SGD Pharma, announces its commitment to company-wide emissions reductions as part of its decarbonization strategy by joining the Science Based Targets initiative (SBTi).

Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.

Our packed agenda will highlight how the Oxford Nanopore platform can generate richer data revealing enhanced biological insights not possible with short read sequencing – or other sequencing platforms – to accelerate research into human disease.

The partners will offer an integrated sample-to-report rapid nanopore sequencing analysis platform for neonatal/paediatric intensive care units to support clinicians in acute settings.

CEO Gordon Sanghera discusses how Apple’s latest product announcement means complex processing required for DNA/RNA sequencing can now be run from the latest MacBook Pro™ or iMac ™.

Consortium aims to share best practices and increase our understanding of genetic disease.

Building on the MAS-seq concatenation method, these three new kits can significantly increase throughput in RNA application.

Partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Lonza launched PyroCell® MAT Rapid System and PyroCell® MAT Human Serum (HS) Rapid System, two sustainable monocyte activation test (MAT) systems containing the new PeliKine Human IL-6 Rapid ELISA Kit.